荷兰反垄断监管机构调查Biogen关于其MS药物检测行为
STAT+: Dutch antitrust regulators probe Biogen over test for its MS drug
荷兰消费者和市场管理局(ACM)调查Biogen,质疑其是否滥用市场主导地位,限制Tysabri治疗患者使用竞争对手的替代药物Tyruko。Biogen为Tysabri患者独家提供免费病毒检测,而拒绝向使用Tyruko的患者提供。
![]()
By Ed Silverman
Nov. 10, 2026
Pharmalot Columnist, Senior Writer
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.
Dutch anti-trust regulators are investigating allegations that Biogen may have abused its dominant position in the market for multiple sclerosis treatments and associated blood tests.
The Netherlands Authority for Consumers and Markets, also known by its Dutch acronym ACM, is probing whether the company reserved a test for patients who are treated with Tysabri, its MS drug, and refusing to make the test available to patients on rival medications, such as Tyruko, a biosimilar version that is sold by Sandoz.
Patients who are treated with Tysabri, Biogen’s biggest-selling medicine, must be regularly tested for the risk of developing progressive multifocal leukoencephalopathy, an infection caused by a virus that may be fatal or result in severe disability. Biogen developed a test for the virus and provides it free of charge — and exclusively — to patients receiving Tysabri.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT 主站 · statnews.com